

Jie Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9531853/publications.pdf>

Version: 2024-02-01

57
papers

2,214
citations

236833

25
h-index

233338

45
g-index

61
all docs

61
docs citations

61
times ranked

3369
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. <i>Neuroscientist</i> , 2022, 28, 254-270.	2.6	9
2	Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. <i>Autoimmunity Reviews</i> , 2022, 21, 102921.	2.5	7
3	Axonal variants of Guillain-Barré syndrome: an update. <i>Journal of Neurology</i> , 2021, 268, 2402-2419.	1.8	38
4	PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 716747.	1.8	11
5	Can Control Infections Slow Down the Progression of Alzheimer's Disease? Talking About the Role of Infections in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 685863.	1.7	8
6	Nuclear factor kappa B inhibitor suppresses experimental autoimmune neuritis in mice via declining macrophages polarization to M1 type. <i>Clinical and Experimental Immunology</i> , 2021, 206, 110-117.	1.1	7
7	Impact of Neurofascin on Chronic Inflammatory Demyelinating Polyneuropathy via Changing the Node of Ranvier Function: A Review. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 779385.	1.4	3
8	The change of PD1, PDL1 in experimental autoimmune encephalomyelitis treated by 1,25(OH)2D3. <i>Journal of Neuroimmunology</i> , 2020, 338, 577079.	1.1	11
9	Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102430.	0.9	11
10	Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 544235.	1.7	38
11	Role of Resolvins in the Inflammatory Resolution of Neurological Diseases. <i>Frontiers in Pharmacology</i> , 2020, 11, 612.	1.6	41
12	Regulation of microglia by glutamate and its signal pathway in neurodegenerative diseases. <i>Drug Discovery Today</i> , 2020, 25, 1074-1085.	3.2	18
13	Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases. <i>Frontiers in Neuroscience</i> , 2019, 13, 869.	1.4	62
14	The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population. <i>Journal of Neuroimmunology</i> , 2019, 337, 577045.	1.1	10
15	Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome. <i>Frontiers in Neurology</i> , 2019, 10, 225.	1.1	10
16	Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. <i>Immunobiology</i> , 2019, 224, 397-401.	0.8	6
17	Promising Neuroprotective Function for M2 Microglia in Kainic Acid-Induced Neurotoxicity Via the Down-Regulation of NF- κ B and Caspase 3 Signaling Pathways. <i>Neuroscience</i> , 2019, 406, 86-96.	1.1	20
18	Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis. <i>Stem Cells International</i> , 2019, 2019, 1-11.	1.2	16

#	ARTICLE	IF	CITATIONS
19	Resolution of inflammation in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 34-41.	0.9	31
20	Effects of Follicular Helper T Cells and Inflammatory Cytokines on Myasthenia Gravis. <i>Current Molecular Medicine</i> , 2019, 19, 739-745.	0.6	8
21	The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2018, 318, 1-7.	1.1	223
22	Roles of macrophage migration inhibitory factor in Guillain-Barré syndrome and experimental autoimmune neuritis: beneficial or harmful?. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 567-577.	1.5	6
23	The efficacy of vitamin D in multiple sclerosis: A meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 56-61.	0.9	50
24	Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis. <i>Mediators of Inflammation</i> , 2018, 2018, 1-10.	1.4	25
25	Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives. <i>Mediators of Inflammation</i> , 2018, 2018, 1-17.	1.4	107
26	Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	52
27	Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression. <i>BioMed Research International</i> , 2018, 2018, 1-5.	0.9	3
28	Neuroprotective effect of matrine on MPTP-induced Parkinson's disease and on Nrf2 expression. <i>Oncology Letters</i> , 2017, 13, 296-300.	0.8	41
29	A case report: Non-alcoholic Wernicke encephalopathy associated with polyneuropathy. <i>Journal of International Medical Research</i> , 2017, 45, 1794-1801.	0.4	7
30	Tumor necrosis factor- α in Guillain-Barré syndrome, friend or foe?. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 103-112.	1.5	15
31	Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target. <i>Molecular Neurobiology</i> , 2017, 54, 7567-7584.	1.9	198
32	Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2653-2660.	1.0	18
33	Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-14.	1.4	66
34	Double Roles of Macrophages in Human Neuroimmune Diseases and Their Animal Models. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	1.4	28
35	Bowman's Birk inhibitor concentrate suppresses experimental autoimmune neuritis via shifting macrophages from M1 to M2 subtype. <i>Immunology Letters</i> , 2016, 171, 15-25.	1.1	11
36	Fasting Glucose Levels Correlate with Disease Severity of Guillain-Barré Syndrome. <i>PLoS ONE</i> , 2015, 10, e0145075.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis. Mediators of Inflammation, 2015, 2015, 1-20.	1.4	53
38	Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored. Mediators of Inflammation, 2015, 2015, 1-12.	1.4	33
39	Follicular Helper CD4 ⁺ T Cells in Human Neuroautoimmune Diseases and Their Animal Models. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	25
40	More Severe Manifestations and Poorer Short-Term Prognosis of Ganglioside-Associated Guillain-Barré Syndrome in Northeast China. PLoS ONE, 2014, 9, e104074.	1.1	15
41	Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments. Mediators of Inflammation, 2014, 2014, 1-10.	1.4	53
42	Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis. Cytokine and Growth Factor Reviews, 2013, 24, 443-453.	3.2	108
43	Attenuated EAN in TNF- α Deficient Mice Is Associated with an Altered Balance of M1/M2 Macrophages. PLoS ONE, 2012, 7, e38157.	1.1	41
44	IFN- γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. Journal of Neuroimmunology, 2012, 246, 18-26.	1.1	28
45	The role of cytokines in Guillain-Barré syndrome. Journal of Neurology, 2011, 258, 533-548.	1.8	79
46	The Immune-Modulatory Role of Apolipoprotein E with Emphasis on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Clinical and Developmental Immunology, 2010, 2010, 1-10.	3.3	66
47	A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. Oncology Reports, 2007, 18, 157-60.	1.2	25
48	Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. International Immunopharmacology, 2001, 1, 1123-1130.	1.7	13
49	The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous System. CNS Neuroscience & Therapeutics, 2001, 7, 387-398.	4.0	178
50	PO protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice. Journal of Neuroscience Research, 2000, 62, 717-721.	1.3	38
51	Dynamics of production of MIP-1 α , MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. Journal of Neuroimmunology, 1999, 98, 168-175.	1.1	59
52	IFN- γ suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. , 1999, 56, 123-130.		26
53	Resistance and susceptibility to experimental autoimmune neuritis in Sprague-Dawley and Lewis rats correlate with different levels of autoreactive T and B cell responses to myelin antigens. Journal of Neuroscience Research, 1998, 54, 373-381.	1.3	13
54	Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. Journal of Neuroimmunology, 1998, 84, 40-52.	1.1	123

#	ARTICLE	IF	CITATIONS
55	High IL-6 and Low IL-10 in the Central Nervous System Are Associated with Protracted Relapsing EAE in DA Rats. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 641-650.	0.9	5
56	Influence of Ion Channel Modulation on in Vitro Interferon- γ Induced MHC Class I and II Expression on Macrophages. <i>Immunopharmacology and Immunotoxicology</i> , 1995, 17, 109-136.	1.1	2
57	Influence of K ⁺ Channel Openers on Interferon- γ Dependent Immune Response in Experimental Allergic Neuritis (Ean). <i>Autoimmunity</i> , 1994, 18, 233-241.	1.2	3